Editor's note: In addition to Elias Dayoub, Anupam Jena and Darius Lakdawalla also coauthored this post. The productivity slowdown in drug innovation has been identified and widely discussed in recent years. In addition, the stagnation in the number
Read More...
Read the complete post at http://healthaffairs.org/blog/2014/06/16/the-end-of-the-blockbuster-implications-for-pricing-of-new-drugs/?utm_source=rss&utm_medium=rss&utm_campaign=the-end-of-the-blockbuster-implications-for-pricing-of-new-drugs
Posted
Jun 16 2014, 12:45 PM
by
Health Affairs Blog